Muscle News and Research

RSS

XenoPort files SPA with FDA for arbaclofen placarbil Phase 3 trial in multiple sclerosis

XenoPort, Inc. announced today that it had reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a pivotal Phase 3 clinical trial of arbaclofen placarbil, previously known as XP19986, as a potential treatment of spasticity in multiple sclerosis patients.

25 Apr 2011

New book on aging

Aging is a natural part of life. From the minute we are born we are heading in one certain direction: towards death. That said, it is possible to arrive at that ultimate destination graceful and vital to our last days rather than chronically ill suffering from one or many debilitating illnesses.

25 Apr 2011

Scientists discover new mechanism behind Salmonella invasion into gut cells

Scientists from the Helmholtz Centre for Infection Research in Braunschweig, Germany have discovered a new, hitherto unknown mechanism of Salmonella invasion into gut cells: In this entry mode, the bacteria exploit the muscle power of cells to be pulled into the host cell cytoplasm.

22 Apr 2011

First UCLA patient with hand transplant doing well at six-and-a-half weeks

Six-and-a-half weeks after receiving the first hand transplant in the western United States, Emily Fennell is becoming so accustomed to her new right hand that she barely remembers when she didn't have one.

21 Apr 2011

Repligen anticipates 30% increase in total revenues for 2011

Repligen Corporation today announced preliminary financial results for fiscal year 2011 which ended March 31, 2011. Total revenue for the year is expected to be $27.3 million compared to $21.0 million in the prior fiscal year, an increase of 30%.

21 Apr 2011

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.

21 Apr 2011

Stealth Peptides launches mitochondrion targeting compound Bendavia at Experimental Biology 2011

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative mitochondrial therapies, introduced its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion, during multiple scientific sessions of the Experimental Biology 2011 meeting.

20 Apr 2011

Testosterone therapy for prostate cancer needs reevaluation: New study

The long-standing prohibition against testosterone therapy in men with untreated or low-risk prostate cancer merits reevaluation, according to a new study published in The Journal of Urology.

20 Apr 2011

New state of myosin in cardiac muscle with low ATP turnover rate could decrease metabolic load of myocardium

New insight into the physiology of cardiac muscle may lead to the development of therapeutic strategies that exploit an inherent protective state of the heart. The research, published by Cell Press online on April 19th in the Biophysical Journal, discovers a state of cardiac muscle that exhibits a low metabolic rate and may help to regulate energy use and promote efficiency in this hard-working and vital organ.

20 Apr 2011

Rituxan receives FDA approval for treating two rare diseases

The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).

20 Apr 2011

Treatment commences in NeuroVive-HCL's 1,000 patient European cardioprotection trial

NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction (the CIRCUS study). NeuroVive's advanced CicloMulsion(TM) cremophor-free IV cyclosporine formulation is used in this study of 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.

20 Apr 2011

Wrong eye operated on by mistake in a 4 year old

Tasha Gaul, mother of 4-year-old Jesse said they had gone to a doctor today to find out if he suffered any permanent damage when a surgeon performed corrective surgery on the wrong eye and then, without consulting the boy's parents, quickly operated on the correct eye. “Right now we're in the dark about what this will be like in the future,” she said. The doctor they saw today told her they will have to wait 5 weeks for his eyes to completely heal before they can determine if there has been any permanent damage.

19 Apr 2011

NeuroVive, HCL initiate CicloMulsion Phase III trial in myocardial infarction

NeuroVive Pharmaceutical and Hospices Civils de Lyon today announced the enrollment and treatment of the first patient in the European multicenter trial of myocardial infarction.

19 Apr 2011

Gene mutation in Tibetian Terrier dogs causes hereditary form of Parkinson's disease in humans

University of Missouri researchers believe both man and animal will benefit from their discovery that the same gene mutation found in Tibetan Terrier dogs can also be found in a fatal human neurological disorder related to Parkinson's disease.

19 Apr 2011

Scientists develop highly efficient approach for cardiac imaging

Scientists of the Charité - Universitätsmedizin Berlin and the Max-Delbrück-Center for Molecular Medicine Berlin-Buch have developed a highly efficient approach for imaging the beating human heart.

19 Apr 2011

Tweaking gene in satellite cells may increase lifespan of people with muscular dystrophy

Researchers have long questioned why patients with Duchenne muscular dystrophy (DMD) tend to manage well through childhood and adolescence, yet succumb to their disease in early adulthood, or why elderly people who lose muscle strength following bed rest find it difficult or impossible to regain.

18 Apr 2011

Scientists identify networks of genes critical in embryonic-heart development

Scientists at the Gladstone Institutes have identified networks of genes that play an important role in embryonic-heart development, advancing knowledge of how healthy hearts develop-and offering clues about how to combat a common birth defect known as congenital heart disease.

18 Apr 2011

Researchers discover strategy that promotes new blood vessel formation

Researchers at The University of Western Ontario have discovered a strategy for stimulating the formation of highly functional new blood vessels in tissues that are starved of oxygen. Dr. Geoffrey Pickering and Matthew Frontini at the Schulich School of Medicine & Dentistry developed a strategy in which a biological factor, called fibroblast growth factor 9, is delivered at the same time that the body is making its own effort at forming new blood vessels in vulnerable or damaged tissue.

18 Apr 2011

Team of researchers study development of mesoderm

During the development of an embryo, a large number of different, specialised cell-types arise from the fertilised egg. The genetic information is identical in all cells of an organism. Different properties of cells arise because the activity of genes is controlled and regulated by so called transcription factors. By switching genes on or off, the body makes muscle cells, bone cells, liver cells and many more.

16 Apr 2011

Eli Lilly receives FDA complete response letter for liprotamase NDA

Eli Lilly and Company has received a complete response letter from the U.S. Food and Drug Administration for its New Drug Application for liprotamase, a non-porcine pancreatic enzyme replacement therapy, under investigation for the treatment of exocrine pancreatic insufficiency.

16 Apr 2011